Condition category
Skin and Connective Tissue Diseases
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status

Plain English Summary

Background and study aims
Eczema (or dermatitis) is a dry skin condition that can affect people in different forms. It can lead to constant scratching, which causes the skin to split and bleed, and leaves it open to infection.
Eczema can be treated using “systemic immuno-modulators”. People with eczema have an overactive immune system that is inflamed. Immuno-modulators are used to suppress the immune system, which in turn reduces inflammation. As they are systemic, they affect the entire body, rather than just one specific area.
Since eczema is a long-term condition, it is important to understand how well such treatments work in terms of improvement in disease control, quality of life and safety over long periods of time. These treatments have undergone careful clinical trials, but the picture we get from clinical trials is not complete. This project aims to fill the gap in knowledge and collect information from patients using systemic immuno-modulators who attend regular dermatology clinics, to better understand the “real world” use of these medicines. It aims to look at side effects, especially for patients taking medication for other conditions, to increase understanding of the risk of using these therapies. It will also look at the "real cost" of these eczema treatments, to examine how much the therapies cost in the long term compared to how well they work.

Who can participate?
Patients with atopic eczema who are about to start a systemic immuno-modulator therapy.

What does the study involve?
Participants will be asked to complete questionnaires in addition to their usual clinic assessments. They will also be asked to donate an optional DNA sample. The study intends to set up a biorepository, which is where patients will be asked to provide optional blood and skin samples to help us better understand how eczema develops and why therapies work better for some people than others, or cause more side effects in others. Donation to the biorepository is a completely optional section of the study.

What are the possible benefits and risks of participating?
There are no additional clinical benefits to participants other than that the information obtained will help the dermatology community better understand the disease and develop more effective treatments in future. There are no known risks to participants taking part in the questionnaire section of the study. For the blood sample collection, the risks may be discomfort and potential bleeding or bruising. For the skin biopsy, the risks include discomfort, infection, scarring, a reaction to local anaesthetic or bleeding.

Where is the study run from?
The study is run from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust.
13 centres across the UK and 1 in Ireland will be open to recruitment in the initial stage of this study, which may later expand. Guy’s an St Thomas’ NHS Foundation Trust is the lead centre.

When is the study starting and how long is it expected to run for?
July 2017 to August 2022. The study may be extended after this date.

Who is funding the study?
The British Skin Foundation (UK)

Who is the main contact?
1. Carsten Flohr (
2. Sonia Serrano (

Trial website

Contact information



Primary contact

Ms Dorothee Boisfer


Contact details

Unit for Population-Based Dermatology Research
St John’s Institute of Dermatology
1st Floor
C Staircase
South Wing
St. Thomas’ Hospital
Westminster Bridge
United Kingdom
02071887188 ext 57716



Additional contact

Prof Carsten Flohr


Contact details

St John's Insitute of Dermatology
1st floor
C Staircase
South Wing
Westminster Bridge Road
United Kingdom

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

The UK-Irish Atopic Eczema Systemic Therapy Register



Study hypothesis

To establish the short- and long-term effectiveness of systemic immune-modulatory therapies in adults and children with atopic eczema

Ethics approval

Wales Research Ethics Committee 1, final ethical approval expected by 08/08/18, IRAS ID: 237309, REC ref. 18/WA/0200

Study design

Observational prospective multi-centre cohort clinical registry

Primary study design


Secondary study design

Cohort study

Trial setting


Trial type


Patient information sheet


Atopic Eczema


During the observation period, participants will be assessed on a regular (3-6 monthly basis) to collect data on disease severity and other clinical outcomes (such as quality of life), adverse events, reasons for potential changes in therapy and key healthcare resource use (e.g. hospitalisations, specialist and GP visits, and drug use). The latter will form part of the health economic feasibility assessment, which will also examine the potential use of HES and CPRD data for health economic evaluation purposes.
Participants will be involved in the study for as long as possible but for a minimum of 1 year. We have incorporated different types for study withdrawal for patients who may not want to attend study visits, but allow us to link their data with healthcare providers, so indirect participation may continue for a long period.

Intervention type



Drug names

Primary outcome measure

Treatment effectiveness will be assessed at the baseline, after 4 weeks, 12 weeks, 6 months, 9 months, 12 months and every 3-6 months thereafter using the following:
1. Physician-assessed severity measures assessed through changes in the following at the baseline, after 4 weeks, 12 weeks, 6 months, 9 months, 12 months and every 3-6 months thereafter:
1.1. EASI (Eczema Area and Severity Index)
1.2. EASI-50
1.3. EASI-75
1.4. IGA (Investigator's Global Assessment)
2. Patient-reported severity measures, assessed through changes in the following at the baseline, 12 weeks and every 6 months thereafter:
2.1. POEM score (Patient Oriented Eczema Measure)
2.2. Quality of life (DLQI/CDLQI/IDQOL) (Dermatology/Children’s Dermatology Life Quality Index)/EQ-5D)
2.3. ACQ score (Asthma control Questionnaire) in patients with a diagnosis of eczema
3. Disease control, assessed as totally or well controlled weeks at the baseline, after 4 weeks, 12 weeks, 6 months, 9 months, 12 months and every 3-6 months thereafter
4. Drug survival and long-term control of disease (time to discontinuation of treatment), assessed using the Kaplan-Meier survival technique and Cox regression analysis.

Secondary outcome measures

1. Pharmacovigilance/safety reporting: All (S)AEs will be recorded at the baseline, after 4 weeks, 12 weeks, 6 months, 9 months, 12 months and every 3-6 months thereafter. Long term linkage data will be used for this purpose as well.
2. Cost-effectiveness analysis: We will calculate the mean costs and assess generic quality of life with the EQ-5D, assessed at the baseline, after 12 weeks, 12 months and every 6 months after, for each treatment group/pathway to inform the development of an economic model. This will be in adherence to NICE (2013) methods guidance – whose objective is to estimate (i) long-term cost and QALYs for each treatment options, and (ii) incremental cost-effectiveness estimates to assess the value for money of each intervention. Value of information analysis will be used to identify those areas for further research which have the highest return in terms of population health
3. Standardised biorepository: blood, leukocytes, serum, skin and swabs collected at the baseline, after 4 weeks, 12 weeks and 12 months.

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Paediatric and adult patients with atopic eczema who due to the severity of their disease and/or impact on quality of life are commencing on or switching to another systemic immuno-modulatory agent (e.g. CyA, AZA, MTX or biologic treatments).
2. Written informed consent for study participation obtained from the patient or parents / legal guardian, with assent as appropriate by the patient, depending on the level of understanding.
3. Consent to participate in long-term follow up and access to all medical records, including hospital admission records and linkage to data held by NHS bodies or other national providers of healthcare data.
4. Diagnosis of atopic eczema in keeping with the UK/Irish diagnostic criteria.
5. Willingness to comply with all study requirements.
6. Competent use of English language, according to patient’s age (capable of understanding patient questionnaires).

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. Insufficient understanding of the study by the patient and/or parent/guardian.
2. Patients who are currently participating in a randomised clinical trial.

Recruitment start date


Recruitment end date



Countries of recruitment

Ireland, United Kingdom

Trial participating centre

Guy's and St Thomas' NHS Foundation Trust
Trust Offices Guy's Hospital Great Maze Pond
United Kingdom

Trial participating centre

The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Freeman Hospital Freeman Road High Heaton
United Kingdom

Trial participating centre

University Hospital Southampton NHS Foundation Trust
Mailpoint 18 Southampton General Hospital Tremona Road
SO16 6YD
United Kingdom

Trial participating centre

Great Ormond Street Hospital for Children NHS Foundation Trust
Great Ormond Street
United Kingdom

Trial participating centre

Manchester University NHS Foundation Trust
Corbett House Oxford Road
M13 9WL
United Kingdom

Trial participating centre

Sheffield Teaching Hospitals NHS Foundation Trust
Northern General Hospital Herries Road
Sheffield South
S5 7AU
United Kingdom

Trial participating centre

Sheffield Children's NHS Foundation Trust
Western Bank
Sheffield South
S10 2TH
United Kingdom

Trial participating centre

University Hospitals Bristol NHS Foundation Trust
Marlborough Street
Bristol Avon
United Kingdom

Trial participating centre

Oxford University Hospitals NHS Foundation Trust
John Radcliffe Hospital Headley Way
Headington Oxford
United Kingdom

Trial participating centre

Royal Hospital for Children
West Glasgow Ambulatory Care Hospital Dalnair Street Yorkhill
G3 8SJ
United Kingdom

Trial participating centre

University of Dundee
United Kingdom

Trial participating centre

University of Edinburgh
Department of Dermatology Lauriston Building Lauriston Place
United Kingdom

Trial participating centre

University Hospital of Wales
CF14 4XW
United Kingdom

Trial participating centre

Trinity College Dublin

Sponsor information


King's College London

Sponsor details

Room 5.31 James Clerk Maxwell Building
57 Waterloo Road
United Kingdom

Sponsor type




Guy's and St Thomas' NHS Foundation Trust

Sponsor details

16th floor
Tower Wing
Great Maze Pond
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type


Funder name

British Skin Foundation

Alternative name(s)


Funding Body Type

private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)


United Kingdom

Results and Publications

Publication and dissemination plan

The study results will be published in peer-reviewed journals and presented at national and international meetings, as well as in the study website ( A publication policy will be drawn up in due course to adequately reflect individual collaborators contributions.

IPD sharing statement:
The data sharing plans for the current study are unknown and will be made available at a later date

Intention to publish date


Participant level data

To be made available at a later date

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

11/08/2020: Recruitment to this study is no longer paused. 24/04/2020: Due to current public health guidance, recruitment for this study has been paused. 25/01/2019: Internal review. 22/01/2019: The following changes were made: 1. The public contact was updated. 2. The acronym was changed from A*STAR to A-STAR.